On September 30, 2022 EXACT Therapeutics AS ("EXACT-Tx" or the "Company") reported that granted 610,643 share options to the Company’s CEO and primary insider, Per Walday (Press release, Exact Therapeutics, SEP 30, 2022, View Source [SID1234621583]). Each option, when exercised, gives the right to acquire one share in the Company. The shares will be subject to a 12-month lock-up, subject to certain exemptions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share options have a ten (10) year term and vest over a period of 36 months, whereby 25% vest after 12 months, 25% vest after 24 months and 50% vest after 36 months. All options have an exercise price of NOK 15, which is subject to adjustment in the event of i) a change in the share capital, ii) a rights issue or repair issue, or iii) dividends or other distributions in cash or in kind.

Following the grant, Per Walday holds a total of 610,643 share options and 0 shares in the Company.

This information is subject to the disclosure requirements in Regulation EU 596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities Trading Act.